Sinco Pharmaceutical Holdings (HKSE:06833) EPS (Basic): HK$0.02 (TTM As of Dec. 2025)


HKSE:06833 Sinco Pharmaceutical Holdings Ltd HKSE:06833
48 GF Score
Price HK$0.16
GF Value HK$0.19
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Sinco Pharmaceutical Holdings EPS (Basic)?

Sinco Pharmaceutical Holdings HKSE:06833 +0.65% 48 EPS (Basic) is HK$0.02 as of Dec. 2025. GuruFocus rates HKSE:06833 with a GF Score™ of 48/100 and a GF Value™ of HK$0.19 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Sinco Pharmaceutical Holdings's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was HK$0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.02.

Sinco Pharmaceutical Holdings's EPS (Diluted) for the six months ended in Dec. 2025 was HK$0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.02.

Sinco Pharmaceutical Holdings's EPS without NRI for the six months ended in Dec. 2025 was HK$0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was 0.02.

During the past 12 months, Sinco Pharmaceutical Holdings's average EPS without NRIGrowth Rate was -17.40% per year. During the past 3 years, the average EPS without NRI Growth Rate was -21.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was -29.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 12 years, Sinco Pharmaceutical Holdings's highest 3-Year average EPS without NRI Growth Rate was 34.60% per year. The lowest was -37.90% per year. And the median was -21.30% per year.

Sinco Pharmaceutical Holdings  (HKSE:06833) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Sinco Pharmaceutical Holdings EPS (Basic) Related Terms

Sinco Pharmaceutical Holdings EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Sinco Pharmaceutical Holdings's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinco Pharmaceutical Holdings EPS (Basic) Chart

Sinco Pharmaceutical Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.04 0.02 0.02 0.02

Sinco Pharmaceutical Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01
HKSE:06833
48GF Score
Sinco Pharmaceutical Holdings Ltd HKSE:06833
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinco Pharmaceutical Holdings EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Sinco Pharmaceutical Holdings's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(38.502-0)/2032.891
=0.02

Sinco Pharmaceutical Holdings's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(11.559-0)/2032.891
=0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of HK$0.02 mean?
Sinco Pharmaceutical Holdings (HKSE:06833) has a EPS (Basic) of HK$0.02 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Sinco Pharmaceutical Holdings and its competitors.
Is Sinco Pharmaceutical Holdings' EPS (Basic) too high?
Sinco Pharmaceutical Holdings' current EPS (Basic) is HK$0.02. Overall, Sinco Pharmaceutical Holdings has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinco Pharmaceutical Holdings' EPS (Basic) compare to MCK and COR?
Sinco Pharmaceutical Holdings' EPS (Basic) of HK$0.02 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Distribution company?
A good EPS (Basic) depends on the Medical Distribution industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Sinco Pharmaceutical Holdings and its competitors. Sinco Pharmaceutical Holdings's current EPS (Basic) is HK$0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinco Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings (HKSE:06833) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.19, compared to a current price of HK$0.16 — trading 17.9% below its estimated fair value. The current EPS (Basic) is HK$0.02. Sinco Pharmaceutical Holdings' overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Sinco Pharmaceutical Holdings (HKSE:06833), the current EPS (Basic) is HK$0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinco Pharmaceutical Holdings (HKSE:06833) Overvalued in 2026?

Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings stock appears to be undervalued. The current stock price of HK$0.16 is trading 17.9% below its estimated GF Value™ of HK$0.19. GuruFocus considers Sinco Pharmaceutical Holdings to be Modestly Undervalued.

Key valuation signals for HKSE:06833:

  • EPS (Basic): HK$0.02
  • GF Value™: HK$0.19 vs. price of HK$0.16 (17.9% below fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the HKSE:06833 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinco Pharmaceutical Holdings Business Description

Address No. 1700, North Section of Tianfu Avenue, E5-1805, Global Centre, High-Tech Zone, Chengdu, Sichuan Province, Chengdu, CHN
Sinco Pharmaceutical Holdings Ltd is an investment holding company that deals in marketing, promotion, and channel management of improved human plasma-based pharmaceuticals, antibiotics, and other pharmaceuticals. The company operates in three business segments, namely biologics, medical aesthetic products, and biopharmaceutical cold chain and supply chain services. The biologics business provides marketing, promotion, and channel management services, while the medical aesthetic products business focuses on research and development, production, and sales of aesthetic medicine in China. The biopharmaceutical cold chain and supply chain services concentrate on the construction of cold chain facilities for biopharmaceutical products and establishing the supply chain service platform.
48GF Score

Get the complete analysis for HKSE:06833

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.16
Price
HK$0.19
GF Value